Ventegra® to Add Celltrion’s Yuflyma®, Biosimilar to AbbVie’s Humira® (adalimumab) as Preferred Formulary Product

Celltrion USA announced that large Medical Benefits Manager Ventegra, will add Yuflyma®, biosimilar to AbbVie’s Humira® (adalimumab) to its formulary as a “preferred drug” by ‘the first part of October 2023’.

On 2 October 2023, Celltrion announced that it received FDA approval for two additional dosages of Yuflyma®.